Prot #PD0053: A Double-Blind, Placebo-Controlled, Randomized, 18-month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease

Project: Research project

Project Details

StatusActive
Effective start/end date7/23/21 → 12/31/24

Funding

  • Parexel (Prot #PD0053 // Prot #PD0053)
  • UCB Biopharma SPRL (Prot #PD0053 // Prot #PD0053)